JP Morgan Upholds Neutral Rating on DocuSign (DOCU)
Written by Emily J. Thompson, Senior Investment Analyst
Source: NASDAQ.COM
Updated: 1 hour ago0mins
JP Morgan's Recommendation: JP Morgan has maintained a Neutral recommendation for DocuSign (NasdaqGS:DOCU) as of December 5, 2025, with an average one-year price target of $96.58/share, indicating a potential upside of 35.84% from its current price of $71.10/share.
Projected Revenue and EPS: DocuSign's projected annual revenue is estimated at $3,043 million, reflecting a decrease of 3.67%, while the projected non-GAAP EPS is 2.78, down 2.93% from previous forecasts.
Fund Sentiment: There are 1,439 funds reporting positions in DocuSign, with a slight increase in ownership by 0.63% over the last quarter, although total shares owned by institutions have decreased by 3.15%.
Shareholder Activity: Major shareholders like iShares Core S&P Mid-Cap ETF and Vanguard Total Stock Market Index Fund have adjusted their portfolio allocations in DocuSign, with some increasing their shareholdings while others have decreased their allocations over the last quarter.
DOCU.O
$0.0000%Past 6 months
Line
|
Candle
1D
5D
1M
3M
6M
YTD
1Y
5Y
No Data
Powered By
Intellectia
Analyst Views on DOCU
Wall Street analysts forecast DOCU stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for DOCU is 97.62 USD with a low forecast of 80.00 USD and a high forecast of 124.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
15 Analyst Rating
5 Buy
10 Hold
0 Sell
Moderate Buy
Current: 71.100
Low
80.00
Averages
97.62
High
124.00
Current: 71.100
Low
80.00
Averages
97.62
High
124.00
Wells Fargo
Equal Weight
downgrade
$85 -> $75
2025-12-05
New
Reason
Wells Fargo
Price Target
$85 -> $75
2025-12-05
New
downgrade
Equal Weight
Reason
Wells Fargo lowered the firm's price target on DocuSign to $75 from $85 and keeps an Equal Weight rating on the shares. The firm notes Q3 was relatively in-line, with TTM billings growth showing steady improvement. Wells remains on the sidelines, however, given still some uncertainty ahead around FY27 setup and investors re-calibrating to a few new metrics.
BofA
Neutral
downgrade
$102 -> $82
2025-12-05
New
Reason
BofA
Price Target
$102 -> $82
2025-12-05
New
downgrade
Neutral
Reason
BofA lowered the firm's price target on DocuSign to $82 from $102 and keeps a Neutral rating on the shares. Q3 results were not going to settle the agentic disruption concerns debate, but the firm was "encouraged" by progress with DocuSign's Intelligence Agreement Management, key to fending off that threat, the analyst tells investors. Following the report, the firm fine-tuned estimates to reflect the results and lowered its target to account for multiple compression across apps.
Morgan Stanley
Equal Weight
maintain
$86 -> $90
2025-09-08
Reason
Morgan Stanley
Price Target
$86 -> $90
2025-09-08
maintain
Equal Weight
Reason
Morgan Stanley raised the firm's price target on DocuSign to $90 from $86 and keeps an Equal Weight rating on the shares. Following a billings beat, the firm is bringing up its topline and operating margin forecasts "slightly" in the out years, the analyst tells investors.
Wells Fargo
Michael Turrin
Equal Weight
maintain
$80 -> $85
2025-09-05
Reason
Wells Fargo
Michael Turrin
Price Target
$80 -> $85
2025-09-05
maintain
Equal Weight
Reason
Wells Fargo analyst Michael Turrin raised the firm's price target on DocuSign to $85 from $80 and keeps an Equal Weight rating on the shares. Post Q1 reset, DocuSign's Q2 provided a billings rebound and commentary on improving trends, the firm says. Wells remains on the sidelines and evaluates durability of changes as tougher second half of the year approaches.
See All Ratings
About DOCU
DocuSign, Inc. provides intelligent agreement management (IAM) platform an eSignature solution, and contract lifecycle management (CLM) solution - allow organizations to increase productivity, accelerate contract review cycles, and transform agreement data into insights and actions. The Company’s IAM platform automates agreement workflows, uncovers actionable insights, and leverages artificial intelligence (AI) capabilities, enabling organizations to create, commit, and manage agreements virtually. Its products include eSignature, CLM, IAM Apps, and Add-on Products. Its Add-on Products include Payments to collect payments along with signed agreements; Identity and standards-based signature for enhanced signer-identification and signatures with digital certification; Notary for remote online notarization; Monitor for advanced analytics; Gen for Salesforce for automated agreement generation within Salesforce, among others.
About the author
Preview
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Sigh Up to Get Intellectia Insights
How did the company's recent strategic decisions impact its latest financial performance?
Can you explain the factors behind the recent changes in the company's stock price?
What are the expected impacts of current market trends on the company's future growth?
Based on the latest earnings report, what are the company's forecasted revenues for the next quarter?